# EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE
> **ANDA214095** · Abbreviated New Drug Application (Generic) · Sponsor: APOTEX · Approved 2026-01-30
## Drug
- **FDA Application Number:** ANDA214095
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE
- **Generic name:** Emtricitabine
- **Active ingredients:** EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** APOTEX
- **First approval:** 2026-01-30
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214095)
---
*MORVS · CC0 1.0*